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1. ENDOMETRIAL CARCINOMAS 
 
The endometrial carcinoma (EC) is a neoplasia of the uterine corpus and isthmus that 
arises from glandular cells of Mullerian derivation. It represents the fourth most common 
cancer cause of death for women in the Industrialized Countries, suggesting that 
environmental and diet factors can increase the risk of endometrial carcinoma onset. The 
risk factors for endometrial cancer can include environmental, hormonal and hereditary-
familiar factors (Lynch syndrome, LS) [1].  
In 1983, Borkhman and colleagues hypothesized the existence of two different endometrial 
cancers types characterized by different pathogenesis [2, 3]: 
? Endometrioid carcinoma type I, estrogen-dependent; 
? Non-endometrioid carcinoma type II, not estrogen-dependent, represented by 
serous, clear cells, mucinous, squamous and undifferentiated adenocarcinoma.  
The first group is characterized by a well differentiated histotype, low stage and it is 
associated to a good prognosis. The second group includes poorly differentiated 
carcinomas with rapid evolution and poor prognosis. 
The molecular pathogenesis is different for the two groups: type I adenocarcinomas are 
mainly characterized by PTEN gene silencing, DNA repair system deficit (i.e. mismatch 
repair system, MMR) and mutations in KRAS, CTNNB1 and PIK3CA genes [4]. On the 
contrary, type II serous adenocarcinomas show TP53 mutations, p16 inactivation, low 
expression of E-cadherin and hyperexpression of HER-2. The immunophenotypical and 
molecular profile of clear cell carcinoma is not well defined yet, but recent data seem to 
focus the attention on ARID1A gene mutations [5]. 
In 2013, the Cancer Genome Atlas Research Network (TCGA) published a genomic 
characterization of 373 endometrial carcinomas (307 endometriod, 53 serous and 13 mixed 
endometrioid-serous) and defined a new classification of endometrial cancer based on 
biomolecular characteristics [6]. Four categories of endometrial cancer are described 
(Figure 1): 
? POLE ultramutated group, characterized by POLE (DNA polymerase ε) 
mutations, high mutational load, rare copy number alterations, frequent C→A 
substitutions, PTEN, PIK3CA, KRAS mutations and good outcome; 
? MSI hypermutated group, characterized by microsatellite instability (MSI) 
caused by mismatch repair (MMR) deficit due to hypermethylation of MLH1 
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promoter, high mutational load, rare copy number alterations, frequent RPL22 
frameshift deletions and KRAS and PTEN mutations; 
? Copy number low group, usually endometrioid G1-G2, characterized by 
microsatellite stable profile (MSS, without MMR defect), low mutational load, 
frequent CTNNB1 mutations; 
? Copy number high group, serous-like, characterized by frequent copy number 
alterations, low mutational load, frequent TP53, FBXW7 and PPP2R1A mutations, 
rare PTEN and KRAS mutations and poor outcome.   
 
 
Figure 1. The Cancer Genome Atlas Research Network molecular classification. 
 
In Table 1 the endometrial histotypes and their incidence are reported. The endometrioid 
carcinomas are the most frequent types and are estrogen-related; they are usually low grade 
(G1-G2, highly or moderately differentiated), which is scored based on the percentage of 
non-squamous solid areas (G1<5%, G2 6%-50% and G3>50%) [7]. The serous-papillary 
carcinoma is the not-endometrioid carcinoma prototype: it is rare (5-10% of all 
endometrial carcinomas), high grade (G3), frequently associated to myometrial and 
vascular invasion, about 75% of cases are stage III at clinical presentation (with peritoneal 
diffuse involvement and/or lymph node metastases) and they have worse prognosis. It can 
be caused by pelvic irradiation or prolonged therapy with tamoxifen and it can be 
associated to breast cancer. The clear-cell carcinoma is typically associated to high grade 
and advanced age and it has poor prognosis. It is more rare than serous carcinoma (2-4%) 
but it may have architectural features similar to serous carcinomas [8-10]. Finally, 
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mucinous, squamous, mixed and undifferentiated histotypes are less frequent (<1%) in 
endometrial site [11]. 
 
Table 1. Endometrial carcinomas histotypes and frequencies [12]. 
Histotype % 
Endometrioid adenocarcinoma 75-80% 
Serous adenocarcinoma <10% 
Clear cell adenocarcinoma 2-4% 
Mucinous adenocarcinomas 1% 
Squamous carcinoma <1% 
Mixed carcinoma <1% 
Undifferentiated carcinoma <1% 
 
 
2. MISMATCH REPAIR SYSTEM  
 
The human mismatch repair system (MMR) is a highly conservative enzymatic complex 
composed by several proteins. Its function is to recognize and repair erroneous 
misincorporation of bases that can arise during DNA replication and recombination, as 
well as to repair different types of DNA damage [13, 14]. The MMR system is composed 
by a heterodimer (MutSα or MutSβ) that recognizes the DNA mismatch and a heterodimer 
(MutLα, composed by MLH1 and PMS2 proteins) that removes and replaces the wrong 
nucleotide with the correct one, as shown in Figure 2. In detail, MutSα (composed by 
MSH2 and MSH6 proteins) recognizes single base mismatch and short DNA loops (shorter 
than 2bp), while MutSβ (composed by MSH2 and MSH3 proteins) recognizes bigger loops 
(from 3bp to 16bp) [15-18]. This process is ATP-dependent and requires the interaction of 
MMR system with exonuclease I and DNA polymerase δ [19-21].   
MMR inactivation leads to the accumulation of errors in highly repetitive sequences, such 
as microsatellite repeats, resulting in a peculiar phenotype called microsatellite instability 
or MSI [22]. Recent works have identified more than 60 target genes, containing 
microsatellite sequences, which are involved in transduction pathways, cell cycle control, 
growth regulation, apoptosis and DNA repair [14]. 
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Figure 2. MMR proteins interaction during the repair of replication errors [14].  
 
 
3. SPORADIC ENDOMETRIAL CANCER WITH MMR 
DEFICIENCY 
 
MMR deficiency and MSI phenotype occur in almost 30% of sporadic endometrial tumors 
[23]. The majority of these tumors shows the inactivation of MLH1 gene, which mostly 
results from promoter hypermethylation rather than somatic mutations or loss of 
heterozygosity [24-27].  
In detail, the silencing event is caused by hypermethylation at CpG sites of MLH1 
promoter as described by Deng et al [28, 29]. Deng and colleagues divided the MLH1 
promoter in four regions [A region (from -711 to -577, containing 23 CpG sites), B (from 
−552 to −266, 19 CpG sites), C (from −248 to −178, 8 CpG sites), and D (from −109 to 
+15, 7 CpG sites)] and correlated the methylation status of each region to the MLH1 
protein expression. Finally, they concluded that methylation status of CpG sites in region C 
provided the best correlation and prediction of MLH1 expression, while methylation in 
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region A seemed not to be critical in silencing the gene expression. It was also suggested 
that methylation in regions B and D could be important in silencing MLH1 expression, but 
methylation in these regions did not provide the best correlation between the methylation 
status and MLH1 expression.  
Recently, Bosse and colleagues identified a correlation between MLH1 methylation and 
immunohistochemical loss of ARID1A protein [5, 30]. The switch/sucrose non-
fermentable (SWI/SNF) subunit ARID1A (AT-rich interactive domain 1A) is a tumor 
suppressor gene located on chromosome 1p36.11 and encodes for a core member of 
SWI/SNF complex [31, 32]. This complex is involved in chromatin remodeling, which is a 
molecular mechanism of regulation of gene expression levels based on ATP-dependent 
changes of nucleosome structure and plays a crucial role in carcinogenesis [32]. ARID1A 
presents four important domains: a DNA-binding domain (ARID domain) that can 
specifically bind an AT-rich DNA sequence; a SWI/SNF interaction domain that interacts 
with SMARCB1 or SMARCA4, two SWI/SNF subunits; a HIC1-binding domain that 
binds HIC1 (hypermethylated in cancer 1 protein); a C-terminus domain that can activate 
glucocorticoid receptor-dependent transcription (Figure 3) [33]. Inactivating ARID1A 
mutations (usually frameshift or nonsense) lead to cancer progression by alterations of cell 
differentiation, migration, adhesion and cell cycle timing [34, 35]. 
 
Figure 3. A) ARID1A structure domains; B) SWI/SNF complex in activation or repression of gene 
transcription. 
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LYNCH SYNDROME AND ENDOMETRIAL CANCER  
 
Lynch syndrome (LS, ORPHA 144, OMIM #120435) is a hereditary disease with 
autosomal dominant transmission and high penetrance (80-85%) characterized by high 
genetic heterogeneity. It is caused by a germline inactivating mutation in one tumor 
suppressor gene that encodes for a protein of MMR system, namely MLH1, MSH2, MSH6 
and PMS2 [36, 37]. 
To date, more than 2360 MMR germline variants have been identified and enclosed in the 
international database called InSiGHT (International Society for Gastrointestinal 
Hereditary Tumours) [38]. These genes do not display any mutational hot spot, as a matter 
of fact the mutations are distributed along the whole gene. MLH1 and MSH2 genes are 
more frequently mutated (40% MLH1 e 34% MSH2), followed by MSH6 (18%) and PMS2 
(8%) [39]. The InSiGHT has recently classified the germline variants in five classes based 
on the clinical significance [38] (www.insight-group.org): class 1, not pathogenic; class 2, 
likely not pathogenic; class 3, variants with uncertain significance (VUS); class 4, likely 
pathogenic; class 5, pathogenic.    
Most of MMR germline mutations generate a stop codon and a non-functioning truncated 
protein [40]. On the contrary, one third of missense variants is VUS and additional tests, 
such as in silico, functional and segregation assays, are needed to better define the clinical 
significance of VUS (according to InSiGHT guideline, www.insight-group.org).  
As reported in literature, the MMR inactivation model follows the Knudson’s two hit 
hypothesis [41]. In LS tumors, the “first hit” is represented by a germline mutation (point 
mutation or large rearrangement), while the “second hit” is acquired at somatic level due to 
different genetic mechanisms (deletion, mitotic recombination, point mutation, genetic 
conversion, loss of heterozygosity) [42]. Recently, Lynch patients with a germline 
epimutation of MLH1 or MSH2 have been described in literature [43]. Epimutations are 
defined as changes that do not involve primary gene sequence, but include epigenetic 
modifications that finally alter the transcription of the gene [42, 44]. The principal 
epigenetic mechanism is cytosine methylation/demethylation in CpG sites of a gene 
promoter [44-47]. In literature, two types of constitutional epimutations are reported:  
? primary epimutation is a modification arising de novo in a patient, reversible 
between generations and then not necessarily heritable;  
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? secondary epimutation is caused by a cis-acting genetic-based alteration, and 
shows a autosomal dominant inheritance pattern. 
As reported by Peltomaki and colleagues, secondary epimutation of MLH1 gene can be 
caused by a deletion in MLH1 5’-UTR, a SNP in MLH1 promoter or a large duplication 
that includes MLH1 gene and its flanking regions. The “second hit” after an epimutation is 
usually the somatic loss of heterozygosity of the wild-type allele [42]. Secondary 
epimutation of MSH2 can be the result of a deletion of 3’-UTR region of the closely linked 
EpCAM gene [48]. MSH6 and PMS2 epimutations have never been reported.  
In LS patients with colorectal cancer, the frequency of constitutional epimutation ranges 
from 2% to 13% for MLH1 and 0%-9% for MSH2 [49, 50]. 
LS patients are characterized by cancer onset in different sites at younger age compared 
with normal population. The tumor spectrum includes colorectal (CRC, 35-55%), 
endometrial (10-45%), ovarian, stomach, pelvic tract, hepatobiliary tract and small bowel 
cancers [51]. In 2005, Lu et al observed that 50% of LS women, affected by endometrial 
and colorectal cancers, showed the endometrial cancer as first manifestation of the 
syndrome, so it was defined as LS “sentinel cancer” [52]. In literature, different cancer 
risks are reported based on which MMR gene is mutated. For instance, a woman carrying a 
MSH6 germline mutation would more likely develop endometrial cancer with respect to 
colorectal cancer, in comparison with patients carrying a MLH1 or MSH2 germline 
mutation [53-55]. Interestingly, PMS2 mutation carriers have 15% of cancer risk to 
develop CRC, 15% for EC and 25-32% of risk to develop other LS tumors up to 70 years 
of age [56]. 
The histopathology of LS associated endometrial tumors is typically endometrioid, but also 
serous, clear cells and mixed histotypes are observed. Carcangiu et al. observed a higher 
number of non-endometrioid histotypes in LS women with respect to non-syndromic 
women (43.5% vs 4.3% respectively) [57]. On the other hand, Garg and Soslow suggested 
that undifferentiated and dedifferentiated endometrial carcinomas are frequently associated 
with mismatch repair abnormalities and Lynch syndrome in addition to the endometrioid 
classical  histotype [58]. Moreover, these ECs are characterized by an abundant “Crohn-
like” lymphocyte infiltrate [53]. 
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DETECTION OF MMR DEFICIENT ECs IN ROUTINE 
DIAGNOSTICS  
 
The recognition of ECs with MMR deficiency is very important in routine diagnostics for 
several reasons.  
First, in the sporadic endometrial carcinogenesis the prevalence of MMR deficient ECs 
represents approximately 20-30% of all endometrial carcinomas [23, 59, 60]. In particular, 
patients that display a MMR deficient ECs show a better prognosis in comparison to 
patients with MMR proficient ECs [59, 60]. Indeed, Kato and colleagues observed a five-
year progression free survival of 92% in MMR deficient tumors with respect to 78% in 
MMR-retained cases and a five-year overall survival of 94% for MMR-deficient tumors in 
comparison to 78% for MMR proficient tumors. Moreover, patients with MMR deficient 
tumors may benefit from immunotherapy [61]. Recently, it was demonstrated that 
neoplasms with a strong host immune response against cancer cell, such as melanoma and 
lung cancer, are greatly sensitive to PD-1 (Programmed cell death protein 1) inhibitors. 
MSI tumors are hypermutated and express many frameshift peptides which act as 
neoantigens that elicit an immune response by tumor-infiltrating lymphocytes [62]. Thus, 
when PD-1 is inhibited, the lymphocytes at the tumor border are activated and attack the 
tumor.  
Secondly, a subset of MMR deficient ECs are associated to Lynch syndrome. The 
identification of LS patients is crucial as they have a higher risk of recurrence and cancer 
onset in other sites compared to normal population and they should refer to a specific 
program of prevention and surveillance [36, 52]. 
In routine diagnostics, the MMR deficiency tests consist in the immunohistochemical 
(IHC) evaluation of the MMR proteins expression and/or the microsatellite instability 
(MSI) analysis. The critical aspects of IHC test regard mainly the careful evaluation of 
internal normal controls, the evaluation of cases with focal/patchy expression of the 
proteins and the recognition of staining artifacts caused by technical problems [63].  
On the other hand, the MSI test is less sensitive than MMR IHC analysis [64], probably 
due to the evaluation of microsatellite loci which are not specific for endometrial site but 
only for the gastrointestinal tumors [65] or to biological characteristics of the endometrial 
cancers which are less unstable, as recently described in a complete NGS microsatellite 
analysis of cancers belonging to 18 different anatomical sites [66].  
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To date, two main panels are being used for the MSI analysis: the Bethesda panel and a 
mononucleotide repeats pentaplex (MRP) panel suggested by Suraweera et al. [67, 68].  
The Bethesda panel includes two mononucleotide repeats (BAT-25 and BAT-26) and three 
dinucleotide repeats (D5S346, D2S123 and D17S250) which are highly polymorphic in the 
population, thus they require the analysis of the corresponding germline DNA [67]. 
Moreover, the interpretation of size alterations in dinucleotide repeats is difficult and can 
lead to misclassification [69]. 
The MRP panel, instead, consists in five mononucleotide repeats (BAT-25, BAT-26, NR-
21, NR-22 and NR-24) which have a very low frequency of polymorphisms in Caucasian 
population and do not require the corresponding germline DNA for comparison [68]. 
Additionally, recent works suggest the evaluation of new microsatellite instability loci 
which have been identified in endometrial tumors, in order to improve the sensibility of 
microsatellite instability analysis in ECs [70-73]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM 
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The operative work of my PhD training in Experimental and Translational Medicine has 
been carried out at the Unit of Anatomical Pathology of Varese Hospital. During my 
doctoral training, we selected a series of 80 gynecological cancers (mainly represented by 
endometrial cancers) belonging to 76 patients who referred to the Oncological Genetic 
Counseling Service of Varese Hospital with a suspect of Lynch syndrome.  
The aim of my doctoral thesis included: 
1. the identification of gynecological cancers (GCs) with mismatch repair (MMR) 
deficiency using different somatic tests, including the immunohistochemical 
evaluation of mismatch repair proteins and the microsatellite instability analysis; 
2. the evaluation of EC-specific microsatellite loci in order to improve the sensitivity 
of MSI analysis; 
3. the identification of hereditary and sporadic MMR deficient GCs using MMR 
germline mutation analysis and MLH1 promoter methylation test; 
4. the molecular characterization of 35 endometrial cancers using a targeted exome 
sequencing of 16 genes involved in endometrial carcinogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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1. Patients and samples 
 
We studied 80 formalin fixed and paraffin embedded (FFPE) gynecological cancers (GCs) 
of 76 patients collected in the last 15 years at the Unit of Pathology of Varese Hospital. All 
patients referred to Cancer Genetic Counseling Service of Varese hospital with the suspect 
of Lynch syndrome (LS) due to a positive family history and/or the manifestation of 
synchronous/metachronous uterine and ovarian cancers, according to Bethesda revised and 
Amsterdam criteria. For this reason, the series included 63 endometrial carcinomas (59 
cases localized in corpus/fundus region and four cases at the isthmus level), 13 ovarian 
cancers and four endocervical carcinomas for completeness (Table 2). 
Two independent pathologists reviewed the histological diagnosis of all samples according 
to the 4th edition WHO classification of tumors of the gynecologic tract and the TNM 
staging system [74]. The grade of differentiation was evaluated in agreement with the 7 th 
edition of AJCC manual [75].   
As shown in Table 2, the series of 80 GCs was composed by 64 endometrioid, eight mixed 
(endometrioid and serous), two serous, two clear cell, two undifferentiated, one mucinous 
histotypes and one carcinosarcoma. Comprehensively, the series included 59 low grade 
tumors (27 G1 and 32 G2) and 19 high grade tumors.   
Clinico-pathological informations of all 80 tumors are summarized in Table 2. 
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Table 2. List of 76 patients and the corresponding 80 gynecological cancers. 
 
Patient 
ID 
Tumor 
ID 
Age of 
onset Site Histotype pT pN Grade 
1 1 53 Endometrium Endometrioid 1a 0 2 
2 2 42 Ovary Serous - - 3 
3 3 47 Endometrium Endometrioid 1a 0 1 
4 4 47 Endocervix Endometrioid 1b 0 2 
5 5 55 Endometrium Endometrioid 1a 0 1 
6 6 46 Endometrium Endometrioid 1a 0 1 
7 7 42 Endometrium Endometrioid 1a 1 1 
8 8 45 Endometrium Endometrioid 1a 0 1 
9 9 45 Ovary Endometrioid 1b - 2 
10 10 46 Isthmus Endometrioid 2 0 2 
11 11 67 Endometrium Endometrioid 1a 0 1 
12 12 46 Endometrium Endometrioid 1a 0 2 
13 13 64 Endometrium Endometrioid 1a 0 1 
14 14 46 Endometrium Endometrioid 1a 0 1 
15 15 48 Endometrium Endometrioid 1a 0 1 
16 16 63 Endometrium Endometrioid 1a 0 2 
17 17 63 Endometrium Endometrioid 1a - 2 
18 18 31 Endometrium Mixed 1b 1 3 
19 19 C 33 Endocervix Endometrioid 1b 2 2 19 E 33 Endometrium Endometrioid 1a 1 3 
20 20 42 Ovary Carcinosarcoma 1c 0 3 
21 21 54 Endometrium Endometrioid - - - 
22 22 62 Endometrium Undifferentiated - - 3 
23 23 42 Endometrium Endometrioid 1a 0 2 
24 24 58 Endometrium Endometrioid - - 3 
25 25 55 Endometrium Endometrioid 1a 0 2 
26 26 51 Endometrium Endometrioid 1b X 1 
27 27 37 Isthmus Endometrioid - 0 2 
28 28 34 Endometrium Mixed 2 0 2 
29 29 O 41 Ovary Endometrioid 1a 0 2 29 I 41 Isthmus Endometrioid - - 3 
30 30 49 Ovary Endometrioid - 0 2 
31 31 53 Endometrium Endometrioid 1a 0 1 
32 32 52 Ovary Mixed 2 - 2 
33 33 40 Ovary Mixed - - 3 
34 34 46 Isthmus Endometrioid - - - 
35 35 60 Endometrium Mixed 1a 0 3 
36 36 54 Endometrium Endometrioid - - 2 
37 37 37 Endometrium Mixed - - 3 
38 38 45 Endometrium Endometrioid 1b 0 1 
39 39 65 Endometrium Undifferentiated - - 3 
40 40 61 Endometrium Endometrioid 1a 0 2 
41 41 56 Endometrium Endometrioid 1a - 1 
42 42 69 Endometrium Endometrioid 1a 0 2 
43 43 54 Endometrium Endometrioid 1a - 2 
44 44 56 Endometrium Endometrioid - - 3 
45 45 53 Ovary Mixed 2b 0 2 
46 46 E 44 Endometrium Endometrioid 1a 0 1 46 O 45 Ovary Mucinous 1a 0 1 
47 47 64 Endometrium Endometrioid 1a 0 1 
48 48 71 Endometrium Endometrioid 1a 0 2 
49 49 54 Endometrium Endometrioid 1b 0 3 
50 50 64 Endometrium Endometrioid 1a 0 3 
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51 51 54 Endometrium Clear Cell 1a 0 3 
52 52 75 Endometrium Clear Cell 1a 0 3 
53 53 62 Endometrium Endometrioid 1a 0 1 
54 54 27 Endometrium Endometrioid - 0 2 
55 55 71 Endometrium Endometrioid 1a 0 2 
56 56 68 Endometrium Endometrioid 3a 0 2 
57 57 35 Endometrium Endometrioid 1a 0 1 
58 58 41 Endometrium Endometrioid 1a 0 1 
59 59 E 48 Endometrium Endometrioid 1a 0 1 59 O 48 Ovary Endometrioid 1a 0 1 
60 60 43 Ovary Endometrioid 1a 0 2 
61 61 56 Endometrium Endometrioid 1a 0 1 
62 62 67 Endometrium Endometrioid 1a 0 2 
63 63 55 Endometrium Endometrioid 1b 0 2 
64 64 41 Endocervix Endometrioid 1b1 0 1 
65 65 57 Endometrium Endometrioid 1a 0 2 
66 66 41 Endocervix Serous 1b 0 3 
67 67 57 Endometrium Endometrioid 1a 0 1 
68 68 44 Ovary Endometrioid 2b 0 3 
69 69 29 Ovary Endometrioid - - 2 
70 70 52 Endometrium Endometrioid 2 0 2 
71 71 60 Endometrium Endometrioid 1a - 1 
72 72 70 Endometrium Endometrioid 1a 0 2 
73 73 57 Endometrium Mixed - 1 3 
74 74 72 Endometrium Endometrioid 1a 0 2 
75 75 53 Endometrium Endometrioid 1a - 1 
76 76 56 Endometrium Endometrioid 1a 0 1 
 
Legend: Endometrium= corpus/fundus of the uterus; Isthmus= isthmus of the uterus  
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2. DNA extraction 
 
Tumor DNA was obtained from formalin fixed and paraffin embedded (FFPE) tissues 
using three representative 8μm sections. The sections of every specimen were treated twice 
with Bio-Clear® (Bio-optica, Milan, Italy) and then rehydrated with a descending scale of 
ethanol. DNA was extracted using a QIAamp® DNA FFPE Tissue kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. Neoplastic areas were manually 
microdissected for DNA extraction and contained at least 35% of tumor cells, to minimize 
contamination by normal cell (Figure 4). 
Each DNA was quantified using Qubit® dsDNA High Sensitivity (HS) Assay kit and 
Qubit® 2.0 Fluorometer (InvitrogenTM, Thermo Fisher Scientific, USA). 
 
 
 
 
 
 
 
 
 
 
Figure 4. Manual microdissection and DNA extraction with column.  
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3. Immunohistochemical analysis 
 
The immunohistochemical analysis was performed on 3μm sections of FFPE tissue using 
the monoclonal antibody listed in Table 3. The sections were dewaxed and rehydrated as 
previously described for DNA extraction and subsequently they were treated with 3% 
H2O2 solution for 10 minutes, in order to inhibit the endogenous peroxidase. The slides 
were heated in a microwave at 720 Watt for 4 cycles of 5 minutes submersed in citrate 
buffer at pH 6.0, in order to expose the antigen. 
Staining was visualized by EXPOSE Mouse and Rabbit Specific HRP/DAB detection IHC 
kit (Abicam®, UK) or Ultravision™ Quanto Detection System HRP (Thermo Fisher 
Scientific, USA) and DAB staining. The sections were briefly colored with hematoxylin, 
dehydrated and, finally, assembled with the coverlids using PER-TEK Mounting Medium 
(Kaltek srl, Italy). 
The samples were considered negative for the protein expression when the nuclear 
positivity was observed only in the internal control (stromal cells, muscular cells, normal 
epithelial cells or lymphocytes), but it was not observed in the cancer cell nuclei.  
 
 
 
 
 
Table 3. Monoclonal antibody used for IHC analysis.  
Antibody Clone Target Dilution Company 
MLH1 G168-15 Whole protein 1/100 BD Pharmigen, USA 
MSH2 FE-11 C-terminal fragment 1/200 Oncogene Research, USA 
MSH6 44 Whole protein 1/200 Transduction Laboratories USA 
PMS2 A16-4 C-terminal fragment 1/200 BD Pharmigen, USA 
ARID1A D2A8U Whole protein 1/400 Cell Signaling Technology, USA 
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4. Microsatellite instability analysis by mononucleotide repeats 
pentaplex (MRP)  
 
The microsatellite instability analysis was performed using a pentaplex panel of 
monomorphic mononucleotide repeats (NR21, BAT26, BAT25, NR24, NR22; Table 4) 
suggested by Suraweera et al [68]. The PCR reaction mix and the thermic profile are 
reported below (Table 5). The PCR fluorescent products were subjected to fragment 
analysis by automated sequencing (ABI PRISM 310, ThermoFisher scientific, USA) and 
analyzed with GeneMapper 4.0. (ThermoFisher Scientific, USA).  
A tumor was considered microsatellite unstable (MSI) when at least two microsatellite loci 
were unstable, showing insertion/deletion of at least 3bp (Figure 5). Moreover, to correctly 
define the microsatellite status for each case we evaluated the electropherogram shape of 
each locus [76] which was defined as “Gaussian” shape (Figure 6A) in typical MSS cases 
or “non-Gaussian” shape when a biphasic (B), a left- or a right-tailed shapes (C and D) 
were observed in MSI cases. Those cases that did not fulfill MSS or MSI criteria were 
classified as “borderline” cases (B-MSI) and further described in Results section (Figure 
6). 
 
Table 4. Position, amplicon size, fluorescent labelling and primer sequence of 
mononucleotide repeats pentaplex (MRP).  
Locus Position Amplicon size (bp) 
Fluorescent 
labelling Primer 
NR-21 14q11.2 104 HEX For: TAAATGTATGTCTCCCCTGG Back: ATTCCTACTCCGCATTCACA 
BAT-26 2p21 116 6-FAM For: TGACTACTTTTGACTTCAGCC Back: AACCATTCAACATTTTTAACCC 
BAT-25 4q12 120 TET For: TCGCCTCCAAGAATGTAAGT Back: TCTGCATTTTAACTATGGCTC 
NR-24 2q11.2 130 HEX For: CCATTGCTGAATTTTACCTC Back: ATTGTGCCATTGCATTCCAA 
NR-22 11q24-25 141 6-FAM For: GAGGCTTGTCAAGGACATAA Back: AATTCGGATGCCATCCAGTT 
 
Table 5. Microsatellite pentaplex reaction mix and thermic profile. 
Reaction mix   94°C 5’  
Primer For 0.3 µM  94°C 50”  
Primer Back 0.3 µM  55°C 50” X 10 
dNTPs 200 µM  72°C 50”  
MgCl2 2 mM  89°C 30”  
GoTaq Promega 2 units  55°C 30” X 20 
Buffer 10X  1X  72°C 30”  
Final volume 15 µl  72°C 10’  
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Figure 5. Shape of a repeat’s plot (BAT26). A) MSS Gaussian shape; B) biphasic MSI aberrant shape; C) 
and D) examples of one tail MSI aberrant shape. 
 
 
Figure 6. MSI analysis results of three illustrative cases. A) a microsatellite stable case, no  shortenings or 
expansions are reported; B) a microsatellite unstable case with shortenings greater than 3bp; C) a borderline 
microsatellite unstable case characterized by the NR24 locus clearly unstable and the other four loci with 
shortenings lower than 3bp. The dotted lines indicate the expected size of each locus. Legend: 
MSS=microsatellite stable, MSI=microsatellite unstable, B-MSI= borderline microsatellite instability 
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5. Microsatellite instability analysis of nine additional loci 
 
After a critical analysis of the literature, we selected nine loci of mononucleotide repeats in 
the coding sequence of seven genes that were altered in at least 25% of MSI GC cohorts 
[70-73]. For each locus, the type of repeats, primer sequences and PCR profiles are 
reported in Table 6, while the reagents and the reaction mix were the same used for MRP 
test. Aliquots of 0.3µl of the PCR fluorescent products were combined with 0.5µl TAMRA 
internal size standard (Applied Biosystems, Foster City, USA) and 16.5ul of deionized 
formamide. After denaturation, fragments were separated by electrophoresis on an ABI 
310 capillary sequencer sequencing (ABI PRISM 310, ThermoFisher scientific, Waltham, 
USA) and analyzed with GeneMapper 4.0. Results were confirmed by direct sequencing 
using the same non-fluorescent primers and BigDye Terminator v1.1 (ThermoFisher 
scientific, Waltham, USA) as previously published by Carnevali et al [77]. A locus was 
scored as unstable when a deletion/insertion of at least one nucleotide was observed. 
 
 
 
Table 6. List of the additional microsatellite loci. 
Legend: TD=Touch-Down PCR, TM=Melting Temperature, bp=base pair 
 
Name 
NCBI 
Reference 
Sequence 
Length and 
location of the 
repeats 
Primer sequence 5’ to 
3’ PCR profile 
PCR 
product 
size 
(bp) 
RPL22 NM_000983 A8, exon 2 ggagcacacttccgttagtt ggtgggtgcaatcaagagtg TD: 70°C-62°C 148 
SRPR NM_003139 A8, exon 4  
tccatgattgagacacgggg 
accacctcagtccttagcac TM: 56°C 145 
MBD6_1 NM_052897 C7, exon 7 ccaagtggggagccattttc gccagcagcgcagaatttaa TM: 56°C 104 
MBD6_2 NM_052897 C7, exon 7 gctttaaattctgcgctgctg tgattcccagctcccatctc TD: 68°C-65°C 126 
MBD6_3 NM_052897 C7, exon 8 cacctacctccagtgtcacc cacactccctcagactcacc TD: 68°C-60°C 149 
NRIP1 NM_003489 A8, exon 3 tgtcctccagttgctcctg tctctctgagtgttcctgagt TD: 63°C-55°C 100 
JAK1 NM_002227 A8, exon 5 agtgtggcgtcattctcca tgagcaaacagatactccagtg TD: 68°C-62°C 108 
JMJD1C NM_004241 A8, exon 9 ccagaatcccagtcaccact actcctctcacacatgcctag TD: 64°C-56°C 109 
SVIL NM_003174 G7, exon 31 cgcgccccttacctatttac ttcttcttcctcttcccgcc TD: 68°C-62°C 134 
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6. MLH1 promoter methylation analysis using MS-MLPA 
 
The SALSA MS-MLPA ME011 Mismatch Repair genes (MMR) Kit (MRC-Holland, 
Amsterdam, The Netherlands) was used to perform MLH1 promoter methylation analysis 
on IHC MLH1 negative tumor. 
This ME011 Mismatch Repair genes probemix was developed to detect aberrant CpG 
island methylation of several MMR genes and included six probes for MLH1 (3p22.1), six 
probes specific for the MGMT promoter region (10q26), four probes for MSH2 (2p21), 
three probes for MSH6 (2p16), three probes for PMS2 (7p22), two probes for MSH3 
(5q14.1), and one probe for MLH3 (14q24.3). The most important methylation region for 
MLH1 expression, the Deng C-region, is from -248 nt to -178 nt before the transcription 
start site and the second most important region, the Deng D-region, is from -9 nt to +15 nt 
(Figure 7) [28, 29]. Additional information, such as probe sequences and chromosomal 
locations can be found at www.mlpa.com.  
All MS-MLPA reactions were done according to the manufacturer’s instructions, using 
100-150ng of DNA. The probemix is added to 5?l of denatured DNA and allowed to 
hybridize for 16 hours at 60°C. Subsequently, the sample is divided in two: one half is 
ligated by adding 10?l of ligase-mix, whereas in the other half ligation is combined with 
digestion by adding 10?l of ligation-digestion mix. These samples are incubated for 30 
minutes at 54°C, then the HhaI enzyme is inactivated by denaturation at 95°C for one 
minute. Since the unmethylated sequences are cut by the restriction enzyme, this process 
results in the ligation of the methylated sequences only. Eight microliters of the two 
aliquots are then amplified in a 25?l PCR reaction using Veriti thermocycler (Applied 
Biosystems, Foster City, USA) with the following thermal protocol: 33 cycles of 
denaturation at 95°C for 20 seconds, annealing at 60°C for 30 seconds and extension at 
72°C for 1 minute with a final extension of 20 minute at 72°C. In order to assess MS-
MLPA reliability two replicates were performed for each sample and positive and negative 
controls using fully methylated DNA (CpGenome Universal Methylated DNA, Millipore) 
and unmethylated DNA (CpGenome Universal UnMethylated DNA, Millipore) were 
included in each MS-MLPA experiment. Aliquots of 1.5?l of the PCR reaction were 
combined with 0.5?l TAMRA internal size standard (Applied Biosystems, Foster City, 
USA) and 13.5?l of deionized formamide. After denaturation, fragments were separated 
and quantified by electrophoresis on an ABI 310 capillary sequencer and analyzed with 
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GeneMapper 4.0. (Applied Biosystems). Values corresponding to peak size (base pairs) 
and peak height were used for further data processing by Coffalyser V7 software (MRC-
Holland). 
Methylation dosage ratio (MR) was obtained by the following calculation: MR= 
(Px/Pctrl)Dig / (Px/Pctrl)Undig where Px is the peak height of a given probe, Pctrl is the 
sum of the peak heights of all control probes, Dig stands for HhaI digested sample, and 
Undig stands for undigested sample. 
A methylation ratio (MR) for a given gene may range from 0 (0% of alleles methylated) to 
1.0 (100% of alleles methylated) and threshold values of 0.3 and 0.7 are suggested by the 
manufacturer to consider a locus as hemi-methylated or fully-methylated, respectively. 
 
 
 
 
 
Figure 7. Representation of MLH1promoter region and list of MS-MLPA probes (ME-011 MRC-Holland, 
Amsterdam, The Netherlands) 
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7. Validation of MS-MLPA results by bisulphite-pyrosequencing 
 
To validate the MS-MLPA results, bisulphite pyrosequencing was used to confirm 
methylation patterns of the MLH1 gene. Bisulfite modification of genomic DNA (300 ng) 
was performed with an EpiTect Bisulfite Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s recommendations. Bisulfite-modified DNA was amplified and sequenced 
by using primers and protocol reported below (Table 7 and 8).  
Pyrosequencing was carried out with PyroGold reagents on a PyroMark Q96 ID system 
(Qiagen, Hilden, Germany). Pyrogram outputs were analyzed by the Pyromark Q24 
software using the Allele Quantification software (Qiagen, Hilden, Germany) to determine 
the percentage of methylated alleles at each CpG site examined. Presence of MLH1 
promoter methylation was scored when the mean value of the percentage of methylated 
alleles was higher than 15%. 
 
 
Table 7. Primer sequence of MLH1 methylation PCR. 
Primer Sequence 
MLH1 For GAGTTTTTAAAAAAGAATTAATAGGAAGAG 
MLH1 Back ATACTACCCCCTACCTAAAAAAATAT 
MLH1 Seq CTACCCCCTACCTAAAAAAATATAC 
 
 
 
Table 8. Reaction mix and thermic profile of MLH1 methylation PCR 
 
 
 
 
 
 
 
 
 
 
Reaction mix      
Primer For 0.4 µM     
Primer Back 0.4 µM  95°C 2’  
dNTPs 200 µM  95°C 25’’  
MgCl2 2 mM  57°C 30’’ X 35 
Epitaq Takara 2 units  72°C 30’’  
Buffer 10X  1X  72°C 5’  
Final volume 50 µl     
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8. Selection of 16 genes involved in endometrial cancer development for 
NGS analysis 
 
In order to further characterize the molecular profiles of endometrial cancers of our 
cohort, we decided to study 16 genes involved in endometrial carcinogenesis through 
genetic and epigenetic mechanisms with MiSeq technology (Illumina, San Diego, 
California, USA). 
First, we identified in literature 16 candidate genes which were reported to be associated 
to endometrial cancer [6, 78-82] and we evaluated the frequency of mutation in 
endometrial cancer for each gene using COSMIC website (Catalogue of somatic 
mutations in cancer, http://cancer.sanger.ac.uk/cosmic, Table 9). Subsequently, we 
designed a custom panel for exon sequencing of these genes using GeneRead DNAseq 
Mix-n-Match Panel (Qiagen), defining 150bp as amplicon size (ideal for low-quality 
fragmented DNA, such as FFPE DNA) and choosing 10 exon flanking bases to cover the 
exon/intron junctions (Figure 8, https://www.qiagen.com/it/shop/genes-and-
pathways/custom-products/custom-array-products/generead-designer/). 
 
Table 9. 16 genes studied with MiSeq. 
Gene position % mutations COSMIC Protein family Function 
MLH1 3p22.2 2%. Mismatch Repair DNA mismatch repair. DNA damage signaling 
MSH2 2p21 2.18% Mismatch Repair DNA mismatch repair. DNA homologous recombination repair. 
MSH6 2p16.3 5.48% Mismatch Repair DNA mismatch repair. DNA homologous recombination repair. 
MSH3 5q14.1 1.41% Mismatch Repair DNA mismatch repair.  
MLH3 14q24.3 3.13% Mismatch Repair DNA mismatch repair. 
TP53 17p13.1 18.63% Cell cycle regulator Growth arrest or apoptosis.  
PTEN 10q23.3 37.69% Phosphatase Modulator of the AKT-mTOR signaling pathway. Antagonizes the 
PI3K-AKT/PKB signaling pathway 
PIK3CA 3q26.3 23% PI 3-Kinases Role in cellular signaling in response to growth factors.  
CTNNB1 3p22.1 17.55% Adherent junctions Key downstream component of Wnt signaling pathway. Regulation 
of cell adhesion 
KRAS 12p21.1 14.8% RAS gene Role in the regulation of cell proliferation; role in promoting 
oncogenic events. 
POLE 12q24.3 6.45% Polymerase ε Catalytic subunit of DNA polymerase epsilon, DNA repair activity. 
POLD1 19q13.3 2.19% Polymerase δ Catalytic subunit of DNA polymerase delta, exonucleolytic activity. 
ARID1A 1p36.1 24.65% BAF chromatin-remodeling 
complex, SWI/SNF 
Transcriptional activation and repression of select genes by 
chromatin remodeling (alteration of DNA-nucleosome topology). 
ARID2 12q12 2.97% BAF chromatin-remodeling 
complex, SWI/SNF 
Transcriptional activation and repression of select genes by 
chromatin remodeling (alteration of DNA-nucleosome topology). 
SMARCA4 19p13.2 3.59% SWI/SNF Transcriptional coactivator cooperating with nuclear hormone 
receptors to potentiate transcriptional activation. 
EZH2 7q36.1 2.19% Polycomb-group (PcG) Maintaining the transcriptional repressive state of genes over 
successive cell generations. 
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Figure 8. Detailed flowchart for a custom panel design. 
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9. Targeted gene sequencing with MiSeq  
 
A subset of 35 endometrial cancers of our cohort was tested with the previously selected 
gene panel in collaboration with Sergio Marchini’s laboratory at “Mario Negri” Institute 
for Pharmacological Research (Figure 9) [83]. Since high-quality DNA is essential for 
obtaining good sequencing results,  tumor DNA  (35 tumor samples) and normal DNA for 
comparison (35 normal samples) were extracted using Maxwell 16 system (Promega, 
Madison, Wisconsin, USA) according to the manufacturer’s protocol in our laboratory. 
Sample quality control (Sample QC) was performed using a real-time PCR assay, Infinum 
FFPE QC kit (Illumina, USA). The samples that passed the quality control underwent to a 
target enrichment of the 16 genes using a PCR approach and four pools of primers as 
reported in GeneRead DNAseq Targeted Panels V2 Handbook (Qiagen, Hilden, Germany). 
After the PCR purification using AMPure XP beads and a quality control step performed 
with Agilent 2100 Bioanalyzer (Agilent Technologies), we proceeded with the library 
construction using GeneRead Library I Core Kit and GeneRead Adapter I Set A and B 
(Qiagen, Hilden, Germany) as shown in GeneRead DNAseq Targeted Panels V2 
Handbook. Briefly, the PCR-enriched DNA was cut with an end-repair enzyme, then, after 
a single adenine addition to the DNA ends, a barcode adapter was ligated to the DNA. 
Each sample was tagged with a specific barcode, in order to sequence up to 24 samples in a 
single run. After cleanup of adapter-ligated DNA with AMPure XP beads, the libraries 
were amplified using GeneRead DNA I Amp Kit (Qiagen, Hilden, Germany) according to 
GeneRead DNAseq Targeted Panels V2 Handbook. The amplified libraries were cleanup 
with AMPure XP beads and a quality control step was performed using Agilent 2100 
Bioanalyzer (Agilent Technologies). In the end, 24 libraries were pooled together, loaded 
in a single V2 flow cell and sequenced using MiSeq system. 
Raw de-multiplexed reads were first aligned to the reference human genome (UCSC build 
hg19) using the Burrows-Wheeler Aligner (BWA). Somatic variant calls were detected 
using two different variant caller, MuTect2 and Vardict. Each sample was matched with its 
normal tissue. Then, data were filtered with a coverage of at least 200X and an allelic 
fraction of at least 5% according to NGS analysis on FFPE samples [84-87]. Both 
synonymous mutations outside the splicing regions and variants described in the 1000 
Genome Project were filtered out. 
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Figure 9. GeneRead DNAseq Targeted Panels V2 workflow (Qiagen, Hilden, Germany) 
 
 
 
 
10. Statistical analysis 
 
The statistical analysis was performed using Graph Pad PRISM v.5. Univariate 
comparisons of continuous data were carried out using Student’s t-test and discrete 
variables were compared with χ2 test or Fisher’s exact test. All comparisons were two-
sided and a p-value <0.05 was considered to be significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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1. MMR–DEFICIENCY ANALYSIS  
 
1.1 Immunohistochemical evaluation of MMR proteins 
The immunohistochemical analysis of four MMR proteins (MLH1, MSH2, MSH6 and 
PMS2) was performed in our series. An example of loss of expression of MLH1/PMS2 
proteins is reported in Figure 10. As shown in Supplementary Table 1, we observed a 
normal expression of MMR proteins in 22 out of 80 GCs (27.5%, MMR proficient group, 
p-MMR) while the remaining 58 GCs showed the loss of expression of at least one MMR 
protein (72.5%, MMR deficient group, d-MMR). As shown in Table 10, the p-MMR group 
was composed by 17 endometrial, two endocervical and three ovarian carcinomas, while 
the d-MMR group included 43 endometrial (corpus and fundus), two endocervical, nine 
ovarian carcinomas and four cancers of the isthmus. In the majority of d-MMR cases, we 
observed the combined loss of both eteroduplex proteins (MLH1/PMS2 or MSH2/MSH6, 
Figure 11). We observed the IHC loss of expression of MLH1/PMS2 eteroduplex in 25 
cases (43%), MSH2/MSH6 eteroduplex in 24 cases (41%), MSH6-only in eight cases 
(14%) and PMS2-only in one case (2%). Interestingly, case#55 showed a focal 
MLH1/PMS2 loss of staining in the 60% of the tumor cells, while the remaining 40% 
showed a normal IHC staining of all MMR proteins (Supplementary Table 1). 
 
 
 
 
Figure 10. Example of an endometrioid endometrial cancer (hematoxylin-eosin staining, A) with loss of IHC 
expression of MLH1 (B) and PMS2 (C) proteins.  
 
 
 
A) B) C) 
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Figure 11. Frequencies of different MMR immunophenotypes in the 80 gynecological cancers examined 
 
 
 
 
Table 10. Tumor sites and expression of MMR proteins.  
 
 
 
 
 
 
 
 
Legend: MMR=mismatch repair, GC=gynecologic cancer 
 
 
 
 
 
 
 
 
 
 
 
 
28% 
31% 
1% 
30% 
10% 
p-MMR 
MLH1/PMS2 neg 
PMS2 only neg 
MSH2/MSH6 neg 
MSH6 only neg 
 MMR PROFICIENT (22 GC, 28%) 
MMR DEFICIENT 
(58 GC, 72%) 
Site   
Endometrium (60) 17 43 
Isthmus (4) - 4 
Endocervix (4) 2 2 
Ovary (12) 3 9 
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1.2 Microsatellite instability analysis by mononucleotide repeats 
pentaplex (MRP) 
We evaluated MSI status of 22 p-MMR and 58 d-MMR GCs using MRP. Twenty-one out 
of 22 p-MMR GCs were classified as MSS: 19 cases did not show any alteration and two 
cases showed 1bp deletion at BAT25 locus. Unexpectedly, one p-MMR GC showed a MSI 
profile with shortenings greater than 3bp in NR-21, BAT-25 loci and a non-Gaussian 
repeats shape (case#40, discordant case). 
MRP analysis of 58 d-MMR GCs identified 43 cases with MSI profile, nine B-MSI GCs 
and six GCs with MSS profile (Figure 12). 
 
 
Figure 12. MRP MSI analysis of 80 gynecological cancers. A) Distribution of MSI, B-MSI and MSS cases 
in p-MMR and d-MMR groups. B) Three representative examples of MSS, MSI and B-MSI using MRP test. 
 
The immunohistochemical study of MSI cases revealed the loss of MLH1-PMS2 proteins 
in 19 cases, PMS2-only in one case, MSH2-MSH6 in 21 cases and MSH6-only in two 
cases.  
As shown in Supplementary Table 1, six MMR deficient GCs fulfilled the criteria for MSS 
and were identified as discordant cases (case#38, 39, 43, 45, 54 and 55). Four cases (three 
uterine cancers and an ovarian one) were MLH1-PMS2 negative and two uterine cancers 
were MSH6-only negative. 
B-MSI cases did not satisfy neither MSI nor MSS criteria as they showed 
insertion/deletion smaller than 3bp in at least two loci, although they were characterized by 
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a non-Gaussian repeats shape (case#9, 10, 11, 14, 20, 21, 32, 33 and 41). In detail, four 
GCs showed only one locus clearly unstable (i.e. with shortenings/expansions ≥3bp) and at 
least an additional locus with shortenings/expansions of one or two nucleotides. In the 
remaining five cases, two or more loci showed shortenings/expansions of one or two 
nucleotides. These cases included two endometrial cancers that were MLH1-PMS2 
negative, three MSH2-MSH6 negative GCs (two ovarian and one uterine cancer) and four 
GCs (two ovarian and two uterine cancers) that were MSH6-only negative (Table 11).  
Interestingly, while the MSI cases encompassed comparable percentages of MLH1-PMS2 
negative and MSH2-MSH6 negative cases (20/43 cases and 23/43 cases, respectively), B-
MSI was associated to the MSH2 and/or MSH6 eteroduplex deficit (7/9 cases), but the 
statistical significance was not reached probably due to the small size of this group of cases 
(p=0.3, Figure 13A). Moreover, B-MSI GC were found preferentially among ovarian 
cancers with respect to the other d-MMR cases (4/9 versus 5/50 cases, p=0.02, Figure 
13B). 
Finally, comparing the results from IHC and MRP analysis, we observed a global 
concordance of 91.3% (seven discordant cases: one p-MMR and six d-MMR).  
 
 
Table 11. MMR proteins status and MRP analysis.  
Lege
nd: 
MM
R=m
ismat
ch 
repai
r, 
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ivity, GC=gynecologic cancer, MSS=microsatellite stable, MSI=microsatellite unstable, B-
MSI=microsatellite borderline, *discordant cases 
 
 
Figure 13. Distributions of MSI and B-MSI cases based on IHC results and tumor sites. 
MMR protein 
status 
MSS CASES 
(27 GC) 
MSI CASES 
(44 GC) 
B-MSI CASES 
(9GC) 
MLH1/PMS2 neg 4* 19 2 
PMS2 only neg - 1 - 
MSH2/MSH6 neg - 21 3 
MSH6 only neg 2* 2 4 
No MMR loss 21 1* - 
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1.3 Microsatellite instability analysis of additional loci 
We evaluated the status of nine additional microsatellite loci (Table 6) in the p-MMR (22 
cases) and in 55 d-MMR cases by fragment analysis and Sanger sequencing validation; 
three d-MMR cases were not evaluable for this analysis (Supplementary Table 1, Figure 
14). We never observed alterations in SVIL, JAK1, JMJD1C and in two loci of MBD6 
gene, thus these loci were excluded from further analyses. As reported in Figure 14, in 26 
out of 55 d-MMR GC (47.3%) at least one of the remaining loci (RPL22, SRPR, NRIP1 
and MBD6_3) was unstable. Moreover, at least one of these loci was mutated in one p-
MMR case (case#40, IHC-MRP discordant case) in agreement with MRP analysis.  
  
 
Figure 14. Additional loci MSI analysis of 77 gynecological cancers. A) Distribution of MSI (at least one 
additional locus mutated) and MSS cases in p-MMR and d-MMR groups.  B) Representative RPL22 
instability by fragment analysis (case #40). C) Confirmation of RPL22 instability by Sanger sequencing. 
 
In detail, RPL22 was mutated in 38.2% of d-MMR cases, followed by SRPR (16.4%), 
NRIP1 (4%) and MBD6_3 (2%). Overall, these additional loci had a lower concordance 
with IHC with respect to MRP analysis (61% vs 91.3%, Table 12). Notably, one case of six 
discordant d-MMR cases which resulted MSS by MRP test (case#55) and the only 
discordant p-MMR case (case#40, MSI without any MMR protein loss) showed instability 
at RPL22 locus. This locus was strongly associated to MLH1-PMS2 defects as in this 
group 13 cases (54.1%) were RPL22 unstable versus seven mutated cases in MSH2-MSH6 
group (22.6%, p=0.023, Figure 15). Moreover, RPL22 and/or SRPR were unstable in three 
out nine B-MSI GCs (33.3%), suggesting that these loci could be used to better 
characterize this subset of cancers. Using both MRP panel and these two additional loci, 
A) 
B) 
C) 
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we observed a global concordance with IHC analysis of 93.5% (72/77 cases evaluable with 
both methods). 
 
 
 
Table 12. MMR proteins status and additional loci MSI analysis.  
 
 
 
 
 
 
 
 
 
 
 
Legend: MMR=mismatch repair, neg=negativity, GC=gynecologic cancer, MSS=microsatellite stable, 
MSI=microsatellite unstable, *at least an additional locus mutated 
 
 
 
 
Figure 15. Distributions of RPL22 mutated and wild-type cases based on IHC results. 
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2. HEREDITARY AND SPORADIC MMR DEFECT 
In order to distinguish sporadic cases from Lynch syndrome patients, the germline 
mutational analysis and MLH1 promoter methylation test were performed for those 
patients that displayed a cancer with MMR IHC loss of staining and/or MSI status (58 d-
MMR GCs and one p-MMR GC, case #40), for a total of 56 patients (three patients 
showed double synchronous/metachronous cancers). All 56 patients who were tested for 
MMR germline analysis have previously signed an informative consent. 
 
2.1 MMR germline mutation analysis 
The germline analysis of MLH1, MSH2, MSH6, PMS2 and EPCAM genes was performed 
at the Experimental Oncology laboratory (National Cancer Institute, CRO Aviano, Italy) 
directed by Dr. Alessandra Viel, using Sanger sequencing analysis for the detection of 
germline variants in the coding sequence or in the exon-intron junctions and MLPA assays 
(kit SALSA-P003 e SALSA P-284, MRC Holland) for the detection of large 
rearrangements of the genes. According to IARC (International Agency of Research on 
Cancer) classification, 26 out of 56 patients carried a pathogenic variant of a MMR gene 
(class 5, 46.4%), while 14 patients displayed a variant with uncertain significance (VUS, 
class 3, 25%) which segregates with disease. No germline variants were identified for 16 
patients (28.6%, Supplementary Table 1).   
Considering each single MMR gene, we identified nine MLH1 germline variants (7 
pathogenic variants and 2 VUS), 12 pathogenic MSH2 variants, 17 MSH6 variants (5 
pathogenic variants and 12 VUS) and 2 pathogenic PMS2 variants (Figure 16).  
As shown in Supplementary Table 1, these mutations were 16 missense variants, seven 
frameshift variants, 12 variants in non coding regions (five in splice donor or acceptor sites 
and seven in UTR regions) and five large deletions (detected with MLPA analysis).  
Interestingly, three out of seven patients with IHC/MSI discordant GCs (cases#38, 39 and 
40) carried a MSH6 or MLH1 germline variant as shown in Supplementary Table 1. 
The 16 patients, that did not display a MMR germline variant, were composed by 15 
patients that harbored MLH1-PMS2 IHC negative GCs and one patient with MSH2-MSH6 
negative cancer (case#44). 
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Figure 16. MMR germline variants frequencies. P=pathogenic variant (IARC class IV or V); VUS=variant 
with uncertain significance (IARC class III). 
 
2.2 MLH1 promoter methylation analysis  
MLH1 promoter methylation analysis was performed using MS-MLPA on 24 GCs 
showing loss of MLH1 protein expression and on case#40, exhibiting MSI but no IHC loss 
of any MMR protein. Moreover, the MS-MLPA results were validated using bisulfite-
pyrosequencing analysis of MLH1 promoter methylation.  
The results of this analysis are reported in Table 13: all samples that showed a methylation 
ratio (MR) greater than 0.3 in C, D and intron regions were considered methylated (M, in 
yellow). The samples showing a MR greater than 0.3 in A and B regions only were not 
considered methylated (U, unmethylated), because, as suggested by literature, the 
methylation of these two regions is not predictive for MLH1 gene silencing [28, 29]. 
In detail, 14 GCs (12 endometrial and two ovarian cancers) showed methylation of all 
MLH1 promoter regions, two cases exhibited methylation in A, B and C regions (case#5 
and case#6). B and/or A region showed methylation in three samples (case#23, case#40, 
case#42) that were considered unmethylated. Interestingly, Case#55, which presented a 
clonal MLH1/PMS2 IHC negativity (in 60% of cancer cells) and MSS phenotype, showed 
an atypical methylation pattern with respect to the other cases. Indeed, C region in this 
sample showed low levels of methylation that were detected only by bisulfite-
pyrosequencing but not by MS-MLPA analysis (Table 13). 
Notably, in three out of seven IHC/MSI discordant cases (cases#45, 54 and 55) we 
observed MLH1 promoter methylation as shown in Supplementary Table 1.  
 
 
 
 
30%
12% 
30% 
18% 
5% 5% 
MSH2 P 
MSH6 P 
MSH6 VUS 
MLH1 P 
MLH1 VUS 
PMS2 P 
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Table 13. MLH1 promoter methylation analysis. 
P  
ID 
T  
ID Site MSI IHC 
MLH1 METHYLATION 
MMR germline 
variant 
(IARC classification) 
Somatic 
(MS-MLPA) Somatic 
(PYRO) Germline A B C D In  
2 2 Ov MSI 
M
LH
1-
PM
S2
 n
eg
 
     U U - MLH1 (class 5) 
3 3 End MSI      U U - MLH1 (class 5) 
4 4 Cerv MSI      U U - MLH1 (class 5) 
11 11 End B-MSI      U U - MLH1 (class 3) 
36 36 End MSI      U U - MLH1 (class 3) 
43 43 End MSS      U U - wt 
42 42 End MSI      U U - wt 
23 23 End MSI      U U - PMS2 (class 5) 
5 5 End MSI      M M U MLH1 (class 5) 
6 6 End MSI      M M M MLH1 (class 5) 
13 13 End MSI      M M U MLH1 (class 5) 
41 41 End B-MSI      M M U wt 
45 45 Ov MSS      M M - wt 
46 
46 E End MSI      M M 
U wt 
46 O Ov MSI      M M 
47 47 End MSI      M M U wt 
48 48 End MSI      M M U wt 
49 49 End MSI      M M U wt 
50 50 End MSI      M M U wt 
51 51 End MSI      M M U wt 
52 52 End MSI      M M U wt 
53 53 End MSI      M M U wt 
54 54 End MSS      M M U wt 
56 56 End MSI      M M U wt 
55 55 End MSS      M M U wt 
40 40 End MSI p-MMR      U U - MLH1 (class 5) 
Legend: P ID=patient ID, T ID=tumor ID, End=endometrium, Ov=ovary Cerv=endocervix, Isth=isthmus, 
yellow=methylated MLH1 region, U=unmethylated, M=methylated, PRO/MSI=IHC proficient/microsatellite 
instable, IARC=International Agency for Research on Cancer, wt= no MMR germline variant (MLH1, 
MSH2, MSH6 or PMS2) 
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2.3 MLH1 promoter methylation and MMR germline mutations in 
sporadic and LS tumors 
As shown in Table 13 and in Figure 17, among the nine MLH1 promoter unmethylated 
GCs, five patients displayed a germline MLH1 or a PMS2 pathogenic variant, two cases 
presented a MLH1 VUS and two cases did not display any MMR germline variant 
(case#42 and 43).  
Notably, three LS patients (case#5, 6 and 13) harbored cancers with MLH1 promoter 
hypermethylation (Table 13 and Figure 17). Case#6 was particularly interesting and it was 
recently published by Cini et al. [44]: the MLPA germline analysis of this case (confirmed 
with long-range PCR and direct sequencing) identified a 997 nucleotide deletion in MLH1 
promoter and exon 1 sequences (MLH1 c.-68_c.116+713). This germline alteration was 
associated to a constitutional MLH1 promoter hypermethylation (secondary epimutation) 
and bisulfite sequencing confirmed that the deletion and MLH1 promoter methylation were 
observed in cis.  
 
 
 
 
 
 
Figure 17. Germline MMR mutational landscape and MLH1 promoter methylation status of 59 MMR 
defective GCs (59 IHC MMR defective cases and 1 IHC MMR proficient and MSI case). Top panels 
represent the presence (pink, pathogenic variant or blue, variant with uncertain significance) or the absence 
(white) of MMR germline variants. The bottom panel indicates samples with MLH1 promoter methylation 
(black) or without MLH1 promoter methylation (white).  
n.a.=not analyzed samples (gray); * IHC MLH1-PMS2 negative, no MMR germline variants identified, 
MLH1 unmethylated (case#42 and 43) 
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3. NGS ANALYSIS ON ENDOMETRIAL CANCER 
 
3.1 Targeted gene sequencing on 35 endometrial cancers 
Targeted exome sequencing analysis of 16 genes involved in endometrial carcinogenesis 
through genetic and epigenetic mechanisms, was carried out on 35 endometrial cancers 
(ECs) of our cohort, for which sufficient and good quality DNA was available. As shown 
in Supplementary Table 1, this set of ECs was composed of 18 LS-related cancers (12 with 
MMR pathogenic variants and six with MMR VUS), two MMR deficient cancers of 
patients without any MMR germline mutation but characterized by a strong family history 
suggestive of Lynch syndrome (familial ECs), five MSI sporadic cancers (MLH1 promoter 
methylated ECs) and 10 MSS sporadic cancers (Figure 18). 
 
 
Figure 18. Endometrial cancers analyzed by targeted gene sequencing. 
 
Data were filtered with a coverage of at least 200X and a mutated allelic fraction of at least 
5%, according to NGS recommendations on FFPE samples [84]. Although we observed a 
variable coverage among samples, the number of reads for each analysis was often higher 
than 200X, with a mean coverage of 857 reads (range from 200 to 9169 reads). 
We identified 465 somatic variants mapping in exon regions, UTR or canonical splicing 
sites, which were considered not to be polymorphisms. As shown in Figure 19, these 
mutations were represented by 266 missense variants, 104 variants in non coding regions 
(66 variants in splice donor or acceptor sites, 38 variants in UTR regions), 50 frameshift 
variants, 27 stop codon variants and 18 in frame insertion/deletions. It is interesting to note 
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that while most genes showed a high frequency of missense variants, MSH2 and ARID2 
were mainly characterized by splice variants and PTEN and ARID1A exhibited a high 
number of frameshift mutations (Figure 19). Moreover, POLE, ARID1A, ARID2, EZH2, 
SMARCA4 and MSH2 were significantly more mutated than the other genes (50 vs 13 
mean mutations respectively, p<0.0001, Figure 19).  
 
 
Figure 19. Distribution of somatic variants identified in each gene analyzed. 
 
 
For each gene, we considered the average of mutated allele fractions (AF) in order to 
identify putative driver genes. This analysis highlighted that five genes, namely MSH2, 
PTEN, CTNNB1, KRAS and ARID2, showed significantly higher AF with respect to the 
remaining genes (22.6% vs 12.4%, p=0.0007, Figure 20). These findings allowed us to 
consider these five genes as driver gene in our cohort. 
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Figure 20. Distribution of mutated allele fractions observed for each gene analyzed. Mutated allele fraction 
is defined as the percentage of reads that carried the mutation versus the total reads. 
 
 
Moreover, we found a significant correlation between the number of mutations and the 
microsatellite instability status as, the mean number of variants for each gene was 
significantly higher in MSI cases than MSS ECs (22 vs 4, p<0.0001, Figure 21). 
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Figure 21. Distribution of the number of variants for each gene in MSI and MSS groups. 
 
Furthermore, we detected recurrent gene variants in multiple cases as listed in Table 14. 
Interestingly, these mutations were only observed in MSH2, TP53, KRAS, ARID1A, ARID2, 
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POLE and SMARCA4 genes. To verify the hypothesis that such mutations could have been 
the results of a defective MMR system, we investigated whether these variants 
preferentially occurred in repetitive or microsatellite sequences and if their distribution was 
prevalent in MSI cases. However, none of them fell in a repetitive sequence, except for a 
deletion of a trinucleotide in a context of eight repetitions (ARID1A c. 3999_4001delGCA); 
moreover, these variants were randomly present in both MSI and MSS cases. 
 
Table 14. Detailed list of the more represented somatic variants. 
Gene Somatic variant 
Type of 
variant 
Impact* 
LS 
ECs 
(18) 
familial 
ECs 
(2) 
MSI sporadic 
ECs 
(5) 
MSS sporadic 
ECs 
(10) 
Mean 
AF 
MSH2 c.212-4delT splice MED 5 1 2 2 37.3% 
 c.1881_1884delAGGA frameshift HIGH 4 0 0 0 73.5% 
TP53 c.359A>G missense MED 3 0 3 4 9.5% 
KRAS c.35G>A missense MED 2 0 4 3 23.8% 
 c.38G>A missense MED 1 0 0 1 26.7% 
ARID1A c. 3999_4001delGCA in frame MED 3 1 2 5 6.4% 
 c.5945T>C missense MED 10 2 4 9 7.6% 
ARID2 c.1023+2T>G splice HIGH 12 2 5 10 20.5% 
POLE c.4337_4338delTG frameshift HIGH 2 2 1 0 6.7% 
SMARCA4 c.2062_2063insTCCT frameshift HIGH 3 0 1 2 7.4% 
Legend:*according to MuTect2 and Verdict software; AF=mutated allele fraction (%) 
 
3.2  Targeted gene sequencing on familial and sporadic ECs 
The NGS analysis of normal samples confirmed the presence of all germline MMR 
variants except for the PMS2 variant in case#23 (this gene was not included in the gene 
panel) and a large MLH1 rearrangement, which is known not to be detected by NGS 
analysis (case#6). In all but three LS-ECs (cases#25, 29I and 40), a somatic mutation was 
identified as second hit in the same germline-mutated MMR gene (Figure 22A). 
Interestingly, we observed a high number of MSH2 somatic variants (frameshift or splicing 
variants) in 14 out of 18 LS cancers regardless of the germline variant. In addition, the 
other most frequently mutated genes in LS associated cancers were PTEN, PIK3CA, 
ARID1A, ARID2, POLE and SMARCA4.  
NGS analysis of normal DNA of case#42 and 44 confirmed the absence of germline MMR 
mutations in these patients, according to the previous analyses by Sanger sequencing and 
MLPA. These two familial cases showed a similar somatic mutational profile characterized 
by mutations of MSH2, ARID1A, ARID2 and POLE genes (Figure 22B). Notably, they both 
displayed the same POLE c.4337_4338delTG (mean allelic fraction of 5.65%), ARID1A 
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c.5945T>C (mean allelic fraction of 10.76%) and ARID2 c.1023+2T>G (mean allelic 
fraction of 23.78%) somatic variants (Figure 22B). On the contrary, only case#42 displayed 
PTEN (allelic fraction 38%) and SMARCA4 (allelic fraction 5.4%) mutations while 
case#44 showed a variant in CTNNB1 (allelic fraction 23.5%).   
As shown in Figure 22B, we observed ARID1A, ARID2 and KRAS mutations in all MLH1 
methylated sporadic ECs. Notably, KRAS mutations were significantly associated to MLH1 
methylated sporadic ECs with respect to the other cases (p=0.01). In detail, all MLH1 
methylated ECs (case#47, 48, 49, 53 and 56) were mutated in KRAS gene, while six out of 
18 LS cancers and four out of 10 MSS sporadic cases were KRAS mutated. Moreover, three 
out of five MLH1 methylated sporadic ECs showed PTEN mutations with high mutated 
allelic fraction (mean allelic fraction of 38%). 
As shown in Figure 22B, PTEN, ARID1A and ARID2 were mutated in sporadic MSS ECs. 
Nevertheless, this group did not display any peculiar gene mutation profile.  
 
Figure 22. Heatmap showing the presence/absence of mutations for each gene (row) in Lynch Syndrome 
ECs (columns, in A) or familial/sporadic ECs (columns, in B). Mutations are reported for each patient in a 
blue color scale indicative of allelic fraction (from FA=5% in white to FA=50% in blue). Gray boxes indicate 
wild type sequences at a coverage of 200X. In panel A, top row reports the germline-mutated MMR genes. In 
panel B, familial ECs, sporadic MSI ECs (MLH1 methylated ECs) and sporadic MSS ECs are reported. 
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3.3 Correlation of ARID1A mutations with IHC ARID1A expression 
Based on the results obtained from targeted exome sequencing, we decided to investigate 
ARID1A protein expression using IHC analysis (Supplementary Table 1). An example of 
loss of expression of ARID1A protein is reported in Figure 23B.  
Firstly, we preformed ARD1A IHC analysis on 33 out of 35 ECs analyzed with MiSeq 
(two cases were not available for the IHC analysis) and, secondly, we extended the 
analysis to our entire cohort (only 74 out of 80 GC cases were available). We regrouped 
the two familial cancers which belonged to patients with a strong family history suggestive 
for LS (case#42, 43 and 44) with LS related cases, calling them comprehensively familial 
cases.  
 
 
Figure 23. Examples of two endometrial cancers with positive IHC expression (A, black arrows) and loss of 
IHC expression of ARID1A protein (B, red arrows; positive nuclei of internal control cells, black arrow). 
Hematoxylin-eosin staining of the two representative cases (C and D, respectively).    
A) B) 
C) D) 
ARID1A+ ARID1A - 
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IHC analysis identified nine cases showing ARID1A protein loss, five cases with a focal 
loss of the protein, while the remaining 19 cases did not show any protein loss. When we 
correlated these results with the presence of ARID1A mutations using a mutated allelic 
fraction higher than 5%, we did not observe any correlation. This result was not surprising 
since we detected at least one mutation in ARID1A gene in 31 out of 33 ECs with a mean 
AF of 10.4%. When we decided to consider only ARID1A mutations with a mutated allelic 
fraction higher than 10%, the concordance with IHC ARID1A test raised to 67.7% (21/31 
cases, p=0.05). Moreover, when we extended the ARID1A IHC analysis to all our series 
(Figure 24), ARID1A loss of expression was significantly associated to familial cases 
(55%, 22/40 GCs) compared to MSI MLH1 methylated GCs (23.1%, 3/13 GCs) or MSS 
sporadic cases  (19%, 4/21 GCs, p=0.01). 
 
 
Figure 24. Distribution of ARID1A IHC results among the three groups (familial, MSI MLH1 methylated 
sporadic and MSS sporadic GCs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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MMR-deficiency analysis is an efficient strategy to identify inherited and sporadic 
cancers characterized by microsatellite instability. The identification of MSI GCs is 
important because of the high incidence of MSI tumors among sporadic GCs (30%) [23], 
the earlier onset of these tumors with respect to colon cancers in LS female patients [36, 
52], a favorable clinical outcome [60] and the potential relationship between MSI and 
efficacy of immune checkpoint inhibition [61].  
We decided to select a cohort of patients who referred to Genetic Counseling Service in 
order to enrich the number of MMR deficient GCs. Indeed, IHC and MRP analysis 
identified a larger number of MMR deficient cases (59 GCs, 74%) than that reported in a 
consecutive series of GCs. Considering the immunophenotypical distribution of MMR IHC 
negative cases, we observed 25 MLH1/PMS2 negative cases (43%), 24 MSH2/MSH6 
negative GCs (41%), eight MSH6-only negative tumors (14%) and one PMS2-only 
negative case (2%) in agreement with recent literature [88, 89]. 
 Firstly, we observed a high concordance between MMR IHC analysis and MRP-
MSI test (91.3%), confirming that both these two methods have a high sensitivity in the 
identification of MMR deficient cases in routine diagnostics. According to recent 
literature, most of discordant cases that we identified were characterized by the loss of a 
MMR protein expression and MSS phenotype (6 GCs). By contrast, we observed only one 
case showing MSI in absence of MMR protein expression alterations [64]. In spite of this 
increased sensitivity of IHC analysis, it must be considered that the IHC test requires a 
great experience in the technical set-up, as several critical issues may occur, including a 
correct staining assessment, a careful evaluation of internal normal controls, a cautious 
estimation of cases with focal expression of the proteins and the recognition of staining 
artifacts caused by technical problems [63].  
On the other hand, different hypothesis have been proposed to explain the lower sensitivity 
of MSI test with respect to IHC analysis. Firstly, some authors have suggested that the 
current MSI panel does not include endometrial specific loci as it has been developed for 
the MSI study of colorectal and gastric sites [65]. Secondly, a recent NGS study aimed at 
identifying microsatellite instability in several human cancers revealed that the ECs 
showed the smallest difference between MSI and MSS groups for all instability metrics 
measured, suggesting that the inherent difficulty of the MSI test is caused more likely by a 
biological characteristic of GCs rather than the use of an unsuitable MSI panel [66].  
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Accordingly with this last hypothesis, in our work we identified a subset of ambiguous 
cases that did not fully meet MSI criteria (B-MSI) which were characterized by the 
presence of small microsatellite alterations (<3bp). It is interesting to note that B-MSI are 
frequently found among ovarian cases and they showed preferentially MSH2 and/or MSH6 
negativity, in line with those reports describing an absent or mild MSI phenotype when 
MSH6 gene is involved [90-92].  
The panel of additional tissue-specific loci that we tested resulted less useful with 
respect to MRP panel. In fact, we never observed alterations in SVIL, JAK1, JMJD1C and 
in two loci of MBD6 gene while the remaining four loci (RPL22, SRPR, MBD6_3 and 
NRIP) had a lower concordance with IHC with respect to MRP analysis (61% vs 91.3%, 
p<0.0001). However, we found an association between RPL22 and MLH1 defects 
suggesting for the first time an involvement of RPL22 as a target gene in the MLH1-driven 
pathogenesis. Furthermore, RPL22 and SRPR should be studied in a larger cohort to 
evaluate their utility in supporting MRP panel for MSI testing as the frameshift deletion in 
RPL22 locus was mostly exclusively found in MSI endometrial cancers even by the Cancer 
Genome Atlas Network [6].  
Overall, these data suggest that the integrated use of IHC and microsatellite instability test 
is mandatory for a robust and sensitive MMR-deficiency analysis [64]. Together, these 
approaches compensate for each other's weaknesses and provide reliable data for the 
clinician and the geneticist.  
The second aim of my PhD thesis regarded the characterization of the MMR 
deficiency in sporadic and hereditary GCs, identifying both germline MMR variants 
associated with Lynch syndrome and sporadic MSI cases associated with MLH1 promoter 
methylation. The genetic counseling of all 76 patients together with MMR-deficiency 
results on GCs identified a subgroup of 56 patients (73.7%) who deserved MMR germline 
test. Moreover, the IHC analysis defined which MMR gene should be investigated first 
with germline test, as already observed in literature [36]. 
The analysis of MMR germline variants permitted to identify 18 Lynch syndrome 
patients carrier of a pathogenic mutation (IARC class IV-V variants, 46.4%) and allowed 
these patients and their relatives to participate to a specific program of prevention and 
surveillance. Moreover, we identified a variant with uncertain significance (VUS, IARC 
class III) in 14 out of 56 patients tested (25%) according to literature [93]. VUS represent 
those variants for which pathogenicity has not been demonstrated or excluded in published 
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literature and mutation databases (https://www.insight-group.org/). In our cohort, we 
observed a segregation of the MMR germline VUS with the disease in all analyzed 
families and according to this and to the family history we considered these patients as 
Lynch syndrome cases. Globally, we observed a higher percentage of MSH6 germline 
variants (42%) with respect to other MMR mutations (MSH2 30%, MLH1 23% and PMS2 
5%), in line with those papers that identify a higher number of MSH6 germline variants in 
LS patients who display gynecological cancers [94]. Furthermore, sixteen out of 56 
patients (28.6%) did not carry any MMR germline variant. All MMR wild-type patients 
except one (case#44) displayed a GCs characterized by the loss of IHC expression of 
MLH1/PMS2 proteins. 
The MLH1 methylation analysis was performed on all MLH1 IHC negative GCs 
(15 GCs belonging to MMR wild-type patients and 10 LS-related GCs) with MS-MLPA 
and bisulfite-pyrosequencing analysis. The MS-MLPA is the technique more widely used 
for MLH1 promoter methylation definition because it detects all MLH1 promoter regions 
[95]. On the other hand, the bisulfite-pyrosequencing analysis of MLH1 promoter region C 
provides a quantitative evaluation of the methylation level [96] and, in our series, it was 
sufficient to identify all MLH1 methylated samples. Interestingly, the MMR germline 
analysis together with MLH1 promoter methylation test revealed three cases with both a 
germline pathogenic variant of MLH1 and MLH1 promoter methylation (Case#5, 6 and 
13), suggesting a second hit of inactivation through MLH1 epigenetic silencing. 
Differently, case#6 showed a rare secondary epimutation as described in Cini et al. 
characterized by a high somatic MLH1 methylation level (more than 50%) and germline 
MLH1 promoter methylation [27, 42, 44].  
Finally, we identified three interesting cases (case#42, 43 and 44) belonging to three 
patients with a strong family history suggestive for LS: case#42 and 43 showed MLH1-
PMS2 IHC loss and the absence of MLH1 methylation and MMR germline variants; 
case#44 were MSH2-MSH6 IHC negative but no MSH2 or MSH6 germline mutations were 
identified. According to literature, 32% of patients with MMR deficiency display Lynch-
like syndrome (LLS), which means that they are positive for the clinical criteria of LS 
(Bethesda revised and Amsterdam criteria) but they do not carry any MMR germline 
variant [97]. The cause of tumor MMR deficiency in Lynch-like syndrome cases is likely 
due to either unidentified germline MMR gene mutations, somatic cell mosaicism, or 
biallelic somatic inactivation [98]. 
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The last aspect of my thesis concerned the characterization of the mutational profile 
of hereditary and sporadic endometrial cancers using a targeted exome sequencing panel of 
16 genes involved in endometrial carcinogenesis through genetic and epigenetic 
mechanisms [6, 78-82]. For the first time, we performed a targeted gene sequencing 
analysis on LS and LLS related cancers in comparison to sporadic ECs (with MLH1 
promoter methylation or MSS tumors), while the literature is focused on the mutational 
landscape of sporadic ECs characterized by different clinical or histopathological profiles 
[6, 35, 99-101].  
Targeted exome sequencing was possible in the 35 ECs and matched normal tissues that in 
our cohort yielded sufficient and good quality DNA samples for NGS analysis. We decided 
to filter the data with a coverage of at least 200X and a mutated allele fraction of at least 
5%, in line with recent recommendations using FFPE samples [84-87]. Although the range 
of minimum acceptable coverage varies between different studies, most researchers agree 
that in clinical samples the coverage should be more than 100X and that the variability in 
the total number of reads is an important parameter in order to exclude poor quality DNA 
samples. In this study, we carefully evaluated these technical aspects and we decided to 
adopt strict criteria during data analysis to confidently perform variant quantification [83]. 
The series examined by NGS analysis included almost exclusively endometrioid 
tumors (there was only one undifferentiated EC), encompassing a total of 25 MSI ECs and 
10 MSS ECs. Firstly, we did a comparison between our results and NGS data reported by 
the Cancer Genome Atlas Network, currently the most comprehensive genomic, 
transcriptomic and proteomic characterization ever reported on ECs [6]. In this study the 
authors stratified endometrioid ECs into three main distinct molecular subgroups: 1) an 
ultra-mutated/POLE mutant group with a unique nucleotide change spectrum, 2) a 
hypermutated/MSI tumors group, mostly characterized by MLH1 promoter methylation, 3) 
a group including most of the MSS endometrioid ECs, characterized by low mutation 
frequency and by low somatic copy number alterations. In agreement with this molecular 
classification, our study demonstrated that MSI ECs, including both LS/LLS and sporadic 
ones, showed a significantly higher mutational load than MSS ECs, with a mean of 22 
somatic mutations per tumor in d-MMR group compared with four mutations per tumor in 
p-MMR subset. As already reported for MSI colorectal cancers, this result confirms that 
also MSI ECs, regardless of the origin (hereditary or sporadic) or type of mutation, are 
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hypermutated tumors and may be considered good candidates for checkpoint 
immunotherapy as recently shown in small clinical trials (https://clinicaltrials.gov/).  
The Cancer Genome Atlas Network identified another possible ultramutated 
phenotype in ECs, that is characterized by somatic POLE mutations and, specifically by 
the two mutational hotspot p.V411L and p.P286R [6]. In our series, we did not find any 
case with this molecular profile, although we observed a high number of somatic POLE 
mutations mapping along the whole gene. These mutations were almost exclusively 
observed in MSI tumors (regardless of the hereditary or sporadic origin) and they were 
always low allelic fraction variants (mean allelic fraction of 11.1%) not reported in 
COSMIC database (cancer.sanger.ac.uk/). Although these variants did not occur in 
microsatellite within the coding sequences, altogether these observations suggest that 
POLE may be a target gene in MSI ECs and that “passenger” mutations at low allele 
frequency may contribute to exacerbate the mutator phenotype in these tumors [102]. 
 An important finding of our study regards the comparison of LS/LLS ECs with 
sporadic MSI ECs. The NGS analysis of normal DNA of LS patients confirmed the 
presence of all the germline mutations previously identified in MLH1, MSH2 or MSH6 
genes. The only exception was for a large MLH1 rearrangement that could not be found by 
the target exon sequencing performed in this study.  
In all but three LS-ECs a somatic mutation was identified as “second hit” in the same 
MMR gene with the germline mutation, suggesting that the somatic inactivation of the 
second allele frequently occurs by a mutational event in these cases. Interestingly, in 
addition to the biallelic inactivation of a specific MMR gene, a high frequency of MSH2 
somatic variants (frameshift or splicing variants) was observed in LS/LLS cancers 
regardless of the germline variant. Interestingly, these MSH2 mutations showed high AF 
(Figure 20), suggesting a clonal selection of these mutations in the majority of LS/LLS ECs 
although, based on MSH2 immunohistochemical data, MSH2 protein expression was not 
compromised. 
As expected, MSI sporadic ECs were characterized by MLH1 methylation. Interestingly, 
although these cases showed complete loss of MLH1 protein, we never observed a biallelic 
methylation of the promoter. On the other hand, somatic mutations in MMR genes were 
less frequent in MSI sporadic ECs compared with LS/LLS ECs, and a MLH1 mutation was 
observed in only one case (allelic fraction of 5.1%). 
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The main observation in MSI sporadic ECs was that KRAS mutations were significantly 
associated to MLH1 methylation (p=0.01). In this work for the first time, we observed this 
correlation in ECs and appears to be very intriguing as recent literature demonstrated that 
specific pathways mediate MLH1 silencing in BRAF or KRAS mutant colorectal cancers 
[103-105], suggesting a general model by which different oncoproteins can orchestrate 
promoter hypermethylation and transcriptional silencing of tumor-suppressor genes during 
cancer development.  
Finally, considering the whole series of ECs examined by NGS, the most frequent 
mutated genes were PTEN, ARID1A and ARID2, regardless of MSI status (Figure 22). 
While PTEN is a well-known driver gene in endometrial endometrioid carcinogenesis, 
little is known about the involvement of ARID family genes, coding for proteins of 
SWI/SNF chromatin remodeling complex [106]. Indeed, recent informations on ARID 
genes are emerged from comprehensive genome-wide analyses by NGS. ARID1A 
mutations have been found in various types of cancer and occur at high frequency in 
endometrioid ECs and in endometriosis-associated ovarian cancer [107]. ARID1A 
mutations induces changes in expression of multiple genes, including MLH1, via 
chromatin remodeling dysfunction and have been shown to be associated to PI3K-AKT 
alterations in many immunohistochemical works [30, 107-109]. Moreover, in a recent 
WES analysis of 13 ECs conducted by Liang and colleagues, they identified 12 potential 
driver genes for endometrial carcinogenesis including ARID1A and demonstrated the role 
of this gene as a novel regulator of PI3K pathway activity [90]. Since ARID1A mutations 
occur at the early stage of ECs, availability of a screening method for the detection of 
ARID1A mutations together with the activation of PI3K/AKT pathway would be very 
useful for early diagnosis of ECs. To this regard, the immunohistochemical analysis of 
ARID1A has been proposed as a quick and economic surrogate of mutation analysis, as it 
was suggested that mutations spanning the whole gene are highly correlated with loss of 
protein expression [30]. In this study, we evaluated the immunohistochemical expression 
of ARID1A in 74 GCs of our cohort, composed by 58 endometrial cancers (ECs), 12 
ovarian carcinomas and four endocervical cancers. We found loss of expression of 
ARID1A protein in 39% of the tumors, in agreement with the recent literature [107]. 
Moreover, we performed a preliminary correlation between loss of IHC expression of 
ARID1A and the mutation status of the gene in the subset of the 33 ECs examined by 
NGS. For this analysis we decided to only include ARID1A mutations with a mutated 
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allelic fraction higher than 10% (excluding low allelic fraction variants ranging from 5% to 
10%) and we obtained a concordance of 67.7% that globally reflects data previously 
reported [107].  
A novel finding in this study was the observation that ARID1A IHC loss is significantly 
associated to LS/LLS related cancers compared to sporadic GCs (p=0.01). Although these 
data should be validated in a larger cohort, they suggest a different involvement of 
SWI/SNF complex in the familial endometrial carcinogenesis with respect to the sporadic 
one.  
This study presented some limitations. First, we could not provide correlations with 
prognosis as a complete and long-term follow-up was not available for all patients. 
Secondly, the analyses were conducted on a small size cohort, as we decided to include 
only suspected LS patients in our series. Finally, as the NGS results were collected at the 
end of the PhD internee, we could not validate these findings with a second approach such 
as Sanger sequencing or qPCR. Nevertheless, we plan to develop a prospective research 
work starting from the thesis results, in order to improve these limitations.  
In conclusion, the combined use of MMR IHC analysis and MRP-MSI test is a sensitive 
and reliable strategy to identify MMR deficient GCs. The analysis of coding 
microsatellites in RPL22 and SRPR genes as well as MLH1 promoter methylation test can 
be useful in the evaluation of ambiguous MSI GCs.  
A comparative analysis of genetic and epigenetic features of LS/LLS and sporadic ECs 
provides useful insights into disease biology and diagnostic classification of these tumors. 
Integrated analysis of germline mutations in MMR genes, MLH1 promoter methylation and 
somatic mutations in a small panel of driver genes for ECs allows the recognition of 
peculiar molecular subgroups that may impact on clinical management of these patients. 
Figure 25 reports a schematic presentation of the relevant points of this work. 
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Figure 25. Schematic presentation of the relevant points.   
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SUPPLEMENTARY TABLE 
 
 
 
 
 
 
 
Supplementary Table 1. Comprehensive data of 80 gynecological cancers 
P 
ID 
T 
ID Site Histotype G IHC 
MRP MSI Additional loci analysis Germline mutation 
MLH1 met IHC ARID1A 
MSI NR21 BAT26 BAT25 NR24 NR22 Shape RPL22 SRPR MBD6_3 NRIP1 Germline variant IARC class 
2 2 Ov Serous 3 
M
L
H
1
-
P
M
S
2
 
n
e
g
 
MSI -5 -8 -3 -3 -3 + MUT wt wt wt MLH1 del ex8 5 U - 
3 3 End Endom 1 MSI -2 -4 -4 -1 -4 + MUT wt wt wt MLH1 c.1459C>T 5 U + 
4 4 Cerv Endom 2 MSI -4 -8 -6 -3 -3 + MUT wt wt wt MLH1 c.1459C>T 5 U - 
5 5* End Endom 1 MSI -1 -3 -5 -3 -2 + MUT wt wt MUT MLH1 c.1852delAAG 5 M - 
6 6* End Endom 1 MSI -7 -11 -7 -7 -5 + MUT MUT wt wt MLH1 c.-68_c.116+713 5 M + 
13 13* End Endom 1 MSI -1 -3 -1 -3 s + MUT wt wt wt MLH1 c.458_462delAGGAC 5 M + 
23 23* End Endom 2 MSI -5 -4 1 -2 s + wt wt wt wt PMS2 c.137G>T 5 U + 
36 36* End Endom 2 MSI -4 -6 -7 -3 -5 + wt MUT MUT wt MLH1 c.440G>A 3 U + 
42 42* End Endom 2 MSI -2 -1 -3 -3 -2 + wt wt wt wt wt  U - 
46 
46 
E End Endom 1 MSI -3 -4 -5 -3 -3 + wt wt wt wt wt  
M - 
46 
O Ov Mucinous 1 MSI -3 -3 -4 -1 -2 + MUT wt wt wt M + 
47 47* End Endom 1 MSI -1 -2 -4 -3 -1 + wt MUT wt wt wt  M + 
48 48* End Endom 2 MSI -2 -4 -1 -3 -1 + wt wt wt wt wt  M na 
49 49* End Endom 3 MSI -1 -3 -4 -6 -1 + MUT wt wt wt wt  M - 
50 50 End Endom 3 MSI -2 -3 -3 -3 s + MUT wt wt MUT wt  M + 
51 51 End Clear Cell 3 MSI -1 -3 -7 -4 -2 + ne ne ne ne wt  M + 
52 52 End Clear Cell 3 MSI -2 -4 -2 -3 -3 + MUT wt wt wt wt  M + 
53 53* End Endom 1 MSI -5 -3 -3 -2 -3 + MUT wt wt wt wt  M + 
56 56* End Endom 2 MSI -2 -5 -4 -3 s + MUT wt wt wt wt  M + 
11 11* End Endom 1 B-MSI -1 -1 -1 -4 -1 + wt wt wt wt MLH1 c.790+1G>A 3 U + 
41 41 End Endom 1 B-MSI -2 -2 -4 -2 -1 + wt wt wt wt wt  M + 
43 43 End Endom 2 MSS s -1 s s s - wt wt wt wt wt  U + 
45 45 Ov Mixed 2 MSS s s s s s - wt wt wt wt wt  M + 
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54 54 End Endom 2 MSS s -1 -3 s s - ne ne ne ne wt  M + 
55 55 End Endom 2 MSS -1 s s s s - MUT wt wt wt wt  M - 
22 22 End Undif 3 PMS2 neg MSI -4 -5 -5 -4 -1 + wt wt wt wt PMS2 c.2123delA 5  - 
1 1 End Endom 2 
M
S
H
2
-
M
S
H
6
 
n
e
g
 
MSI -3 -4 -8 -5 -3 + wt wt ne wt MSH2 del ex1-6 5  - 
7 7 End Endom 1 MSI -4 -9 -6 -5 -3 + wt MUT wt wt MSH2 ivs5(+3)A>T 5  - 
8 8 End Endom 1 MSI -4 -4 -2 -7 -3 + wt wt wt wt MSH2 del ex1-6 5  - 
12 12* End Endom 2 MSI -4 -6 -3 -7 -1 + wt wt wt wt MSH2 c.942+3A>T 5  + 
15 15 End Endom 1 MSI -1 -6 -1 -1 -3 + wt wt wt wt MSH2 del ex3-6 5  na 
16 16* End Endom 2 MSI -5 -7 -4 -5 -1 + wt wt wt wt MSH6 c.2764C>T 5  + 
18 18* End Mixed 3 MSI s -3 3 -1 -3 + wt wt wt wt MSH2 c.839T>A 5  - 
19 
19 
C Cerv Endom 2 MSI -1 -6 -4 -2 -2 + wt wt wt wt MSH2 c.839T>A 5  
- 
19 
E* End Endom 3 MSI -2 -3 3 -5 -2 + MUT MUT wt wt  
- 
24 24* End Endom 3 MSI s -3 s -3 -2 + wt wt wt wt MSH2 c.892C>T 5  - 
25 25* End Endom 2 MSI -1 -4 -4 -2 -2 + wt wt wt wt MSH2 c.715C>T 5  na 
26 26* End Endom 1 MSI -6 -5 -2 -3 -3 + MUT wt wt wt MSH2 c.34dupG 5  + 
27 27 Isth Endom 2 MSI -1 -3 -3 s s + wt wt ne wt MSH6 c.*(23_26)dupAGTT 3  - 
28 28 End Mixed 2 MSI s -4 -4 -2 s + wt wt wt wt MSH6 c.*(23_26)dupAGTT 3  na 
29 
29 
O Ov Endom 2 MSI -3 -3 -4 -1 -2 + wt wt wt wt MSH6 c.*(23_26)dupAGTT 3  
+ 
29 
I* Isth Endom 3 MSI -1 -4 -4 -3 -2 + wt wt wt wt  + 
30 30 Ov Endom 2 MSI -2 -4 -6 -2 s + ne ne ne ne MSH6 c.*(23_26)dupAGTT 3  + 
34 34 Isth Endom - MSI -3 -4 -4 -3 -2 + wt wt wt wt MSH6 c.*(23_26)dupAGTT 3  + 
35 35* End Mixed 3 MSI -4 -10 -4 -4 s + MUT wt wt wt MSH6 c.642C>T 3  + 
37 37* End Mixed 3 MSI -4 -4 -3 -5 -2 + wt MUT wt wt MSH6 c.*(23_26)dupAGTT 3  - 
44 44* End Endom 3 MSI -1 -4 -5 -2 -2 + MUT MUT wt wt wt   - 
9 9 Ov Endom 2 B-MSI -3 -1 -1 -1 -1 + MUT MUT wt wt MSH2 c.1216C>T 5  - 
10 10 Isth Endom 2 B- -2 s -4 -2 -1 + wt MUT wt wt MSH2 c.229-230delAG 5  - 
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MSI 
33 33 Ov Mixed 3 B-MSI 1 1 -3 -2 1 + MUT wt wt wt MSH6 c.*(23_26)dupAGTT 3  - 
17 17 End Endom 2 
M
S
H
6
 
n
e
g
 
MSI -5 -2 -1 -1 -3 + wt wt wt wt MSH6 c.2764C>T 5  - 
31 31 End Endom 1 MSI s -4 -4 -2 s + MUT wt wt wt MSH6 c.3632T>C 3  - 
14 14 End Endom 1 B-MSI s -2 -2 -1 -1 + wt wt wt wt MSH6 c.3261delC 5  + 
20 20 Ov Carcinosarcoma 3 B-MSI -1 -1 -2 -1 s + wt wt wt wt MSH6 c.931_935delAAAA 5  - 
21 21 End Endom - B-MSI -1 -2 -1 -2 -2 + wt wt wt wt MSH6 c.4002-23_4002-10del 5  ne 
32 32 Ov Mixed 2 B-MSI s -1 1 -2 1 + wt wt wt wt MSH6 c.3632T>C 3  ne 
38 38* End Endom 1 MSS s s s s s - wt wt wt wt MSH6 c.2314C>T 3  + 
39 39* End Undif 3 MSS s -1 s s s - wt wt wt wt MSH6 c.1184G>A 3  + 
40 40* End Endom 2 
p
-
M
M
R
 
MSI -3 s -3 s -1 + MUT wt wt wt MLH1c.1896+17T>C 5 U + 
57 57 End Endom 1 MSS s s s s s - wt wt wt wt    + 
58 58 End Endom 1 MSS s s s s s - wt wt wt wt    + 
59 
59 
E* End Endom 1 MSS s s s s s - wt wt wt wt 
  
 + 
59 
O Ov Endom 1 MSS s s s s s - wt wt wt wt  
+ 
60 60 Ov Endom 2 MSS s s s s s - wt wt wt wt    + 
61 61 End Endom 1 MSS s s s s s - wt wt wt wt    + 
62 62* End Endom 2 MSS s s s s s - wt wt wt wt    - 
63 63* End Endom 2 MSS s s s s s - wt wt wt wt    + 
64 64 Cerv Endom 1 MSS s s s s s - wt wt wt wt    + 
65 65 End Endom 2 MSS s s s s s - wt wt wt wt    + 
66 66 Cerv Serous 3 MSS s s s s s - wt wt wt wt    + 
67 67 End Endom 1 MSS s s -3 s s - wt wt wt wt    - 
68 68 Ov Endom 3 MSS s s -4 s s - wt wt wt wt    - 
69 69 Ov Endom 2 MSS s s s s s - ne wt ne wt    + 
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70 70* End Endom 2 MSS s s s s s - wt wt wt wt    + 
71 71* End Endom 1 MSS s s s s s - wt wt wt wt    + 
72 72* End Endom 2 MSS s s s s s - wt wt wt wt    + 
73 73* End Mixed 3 MSS s s s s s - wt wt wt wt    - 
74 74* End Endom 2 MSS s s s s s - wt wt wt wt    + 
75 75* End Endom 1 MSS s s s s s - wt wt wt wt    + 
76 76* End Endom 1 MSS s s s s s - wt wt wt wt    + 
  
 
Legend: P ID= patient identification, T ID= tumor identification, *=cases analyzed with NGS; SITE: End=corpus of endometrium, Ov=ovary Cerv=endocervix, 
Isth=isthmus; HISTOTYPE: Endom=endometrioid, Undif=undifferentiated; MMR IHC: pro-MMR=proficient MMR system; MRP test: MSS=microsatellite stable, 
MSI=microsatellite unstable, B-MSI=microsatellite borderline; Additional loci: MUT=new locus unstable, wt=wild-type, ne=not evaluable; germline analysis: 
IARC=International Agency for Research on Cancer; methylation analysis: MLH1 met=MLH1 promoter methylation, M=methylated, U=unmethylated; ARID1A IHC: 
+positive, -negative, ne=not evaluable. 
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